Antiretroviral drugs, used to prevent HIV transmission from mother to child, are now believed to cause genetic damage in infants. This damage, leading to an increased risk of developing cancer, makes it highly plausible these children may be diagnosed with the disease in mid and late adulthood.Two new studies indicate there are cancer-causing effects of transplacental exposure to AZT, an antiretroviral drug. These effects -- like increased incidence of tumors and tumors with genetic changes -- have been demonstrated in mice and rats and seem to be cause for concern in humans too.
"The cumulative mutagenesis data suggest that infants exposed transplacentally to AZT may be at increased risk for cancer as they age," said one researcher, whose findings are published in Environment and Molecular Mutagenesis.
